Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $15.0 million.

  • Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) rose 6.13% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 6.13%. This contributed to the annual value of $14.0 million for FY2024, which is 1.50% down from last year.
  • Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $15.0 million in Q3 2025, which was down 0.01% from $15.0 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $15.1 million for Q2 2021, and its period low was $14.0 million during Q1 2025.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $14.3 million (2023), whereas its average is $14.4 million.
  • In the last 5 years, Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) decreased by 3.00% in 2023 and then increased by 6.13% in 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $14.8 million in 2021, then dropped by 2.33% to $14.5 million in 2022, then fell by 1.44% to $14.3 million in 2023, then declined by 1.50% to $14.0 million in 2024, then grew by 6.13% to $15.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $15.0 million for Q3 2025, versus $15.0 million for Q2 2025 and $14.0 million for Q1 2025.